New FDA-approved drug offers longer survival for pancreatic cancer patients
The FDA has authorized darapinrasib, a drug that targets specific gene mutations in pancreatic cancer, showing a near-double survival benefit in trials.
A federal panel has granted early approval to darapinrasib, a therapy that inhibits gene mutations responsible for pancreatic cancer proliferation. The drug was created by Brian Wolpin’s team at the Hale Family Center for Pancreatic Cancer Research, Dana Farber Cancer Institute. Clinical trial results showed patients who had exhausted other options lived almost twice as long when darapinrasib was paired with an immune-stimulating drug, reaching a median survival of about 13 months.
The FDA’s decision came more than six months before the planned timeline, reflecting the urgent need for new options in a disease that kills roughly 97% of stage-4 patients within months. While some resistance to the medication emerged, participants reported better quality of life and reduced pain compared with chemotherapy. Ongoing studies are testing the pill with additional treatments to further extend its benefits.
Why it matters
It provides a new, potentially life-extending option for a cancer that has few effective treatments.
In this story
